By Kelly Cloonan
Shares of Portage Biotech climbed after the company reported confirmatory data for its PORT-7 treatment of mesothelioma, supporting plans for a human trial.
The stock rose 21% to $10.23 Monday. Shares have more than doubled over the past 12 months.
The clinical stage immuno-oncology company said Monday its PORT-7, a selective adenosine A2B receptor inhibitor, demonstrated superior single agent activity compared with treatment with single agent anti-PD1 antibody in a murine model.
Combining both PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone, showing favorable immune response and increases in immune effector cells for mice in the trial, the company said.
The treatment is targeted at mesothelioma, an aggressive cancer with limited treatment options.
Portage is now making preparations to begin a first-in-human clinical trial with PORT-7, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 28, 2025 13:20 ET (17:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。